Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mette Soendergaard has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bioactive compounds from Morchella esculenta as potential inhibitors of RNA-binding protein La in ovarian cancer: a molecular modeling and quantum mechanics approach

    by Gbenga Dairo, Matthew N. Ward, Mette Soendergaard, John J. Determan

    La protein is significantly expressed in various malignant tumors, including ovarian cancer (OC), which is related to the poor response to platinum-based chemotherapy. Thus, inhibiting La protein could control the expression of the potential downstream genes involved in promoting proliferation and chemotherapy resistance to OC, which could serve as a therapeutic intervention. Through a molecular docking approach, 12 compounds from Morchella esculenta were screened against the crystal structure of La protein and four hit compounds were identified, including beta-carotene, p-hydroxybenzoic acid, gamma-tocopherol, and alpha-tocopherol, with a binding affinity of − 10.7, − 8.1, − 7.9, and − 7.6 kcal/mol, respectively, higher than pyridine-2-carboxylate (control), with a binding affinity of − 5.2 kcal/mol. To explore the interaction of the hit compounds with the target receptor, they were selected for a molecular dynamic simulation and post-simulation analysis for 100 ns. The result showed promising reliability of the ligands due to a stable interaction with the La protein crystal structure. Furthermore, the drug-likeness and physicochemical chemical properties of the compounds were investigated using ADMET study and density functional theory analysis, respectively, and the result shows that the hit compounds could serve as a promising starting for the development of novel LA protein inhibitors for OC therapeutics. Finally, this study compared HOMO and LUMO values from global hybrids with long-range corrected DFAs, and the result from the two followed the same qualitative pattern while calculating HOMO values; however, MO62X/cc-pVTZ could better predict LUMO values when considering a global hybrid.


  • Open Access

    Improving Pharmacokinetics of Peptides Using Phage Display

    by Mallika Asar, Jessica Newton-Northup, Mette Soendergaard

    Phage display is a versatile method often used in the discovery of peptides that targets disease-related biomarkers. A major advantage of this technology is the ease and cost efficiency of affinity selection, also known as biopanning, to identify novel peptides. While it is relatively straightforward to identify peptides with optimal binding affinity, the pharmacokinetics of the selected peptides often prove to be suboptimal. Therefore, careful consideration of the experimental conditions, including the choice of using in vitro, in situ, or in vivo affinity selections, is essential in generating peptides with high affinity and specificity that also demonstrate desirable pharmacokinetics. Specifically, in vivo biopanning, or the combination of in vitro, in situ, and in vivo affinity selections, has been proven to influence the biodistribution and clearance of peptides and peptide-conjugated nanoparticles. Additionally, the marked difference in properties between peptides and nanoparticles must be considered. While peptide biodistribution depends primarily on physiochemical properties and can be modified by amino acid modifications, the size and shape of nanoparticles also affect both absorption and distribution. Thus, optimization of the desired pharmacokinetic properties should be an important consideration in biopanning strategies to enable the selection of peptides and peptide-conjugated nanoparticles that effectively target biomarkers in vivo.


  • Computational evaluation of bioactive compounds from Viscum album (mistletoe) as inhibitors of p63 for pancreatic cancer treatment

    by Gbenga Dairo, Ayooluwa Ilesanmi, Toheeb Balogun, Matthew Ward, Mette Soendergaard, John Determan

    Pancreatic ductal adenocarcinoma is an aggressive malignancy usually detectable at the advanced stage, with a 5-year survival rate of less than 8%. It has been reported that a gene called tumor-protein 63 (TP63) is expressed in an aggressive form of pancreatic cancer with a squamous signature. Thus, inhibiting the activity of p63 can be a means of treating and managing PDA. Different studies have shown that plant constituents are rich and can be a promising source for discovering drug candidates. The extract from mistletoe (Viscum album) is known to contain anticancer compounds; however, the specific molecular mechanism of the bioactive compounds is unknown. This study examines the pancreatic cancer therapeutic potential of the bioactive compounds in the flavonoid and phenolic acid constituents of mistletoe by adopting structural bioinformatics and advanced theoretical chemistry techniques via molecular docking, molecular dynamics simulation, molecular mechanics/generalized Born surface area (MM/GBSA) calculations, pharmacokinetic analysis, and density functional theory analysis. The six best compounds from the flavonoid constituent with the highest binding affinity ranging from −6.8 kcal/mol to −6.7 kcal/mol were selected with the control gemcitabine (−5.5 kcal/mol) for further computational analysis after molecular docking. Furthermore, MM/GBSA calculation showed the highest binding energy for the selected docked compounds, which validates their inhibitory potential. Hence, the molecular dynamics simulation, post-simulation analysis, pharmacokinetics model, and DFT results showed that mistletoe compounds are reliable due to their stable interaction with the target protein and drug-likeness properties. Communicated by Ramaswamy H. Sarma


  • Open Access

    Computational Evaluation of Bioactive Compounds from Viscum album (Mistletoe) as Inhibitors of p63 for Pancreatic Cancer Treatment

    by Gbenga Dairo, Ayooluwa Ilesanmi, Toheeb Balogun, Matthew Ward, Mette Soendergaard, John Determan

    Pancreatic ductal adenocarcinoma is an aggressive malignancy usually detectable at the advanced stage, with a 5-year survival rate of less than 8%. It has been reported that a gene called tumor-protein 63 (TP63) is expressed in an aggressive form of pancreatic cancer with a squamous signature. Thus, inhibiting the activity of p63 can be a means of treating and managing PDA. Different studies have shown that plant constituents are rich and can be a promising source for discovering drug candidates. The extract from mistletoe (Viscum album) is known to contain anticancer compounds; however, the specific molecular mechanism of the bioactive compounds is unknown. This study examines the pancreatic cancer therapeutic potential of the bioactive compounds in the flavonoid and phenolic acid constituents of mistletoe by adopting structural bioinformatics and advanced theoretical chemistry techniques via molecular docking, molecular dynamics simulation, molecular mechanics/ generalized Born surface area (MM/GBSA) calculations, pharmacokinetic analysis, and density functional theory analysis. The six best compounds from the flavonoid constituent with the highest binding affinity ranging from -6.8 kcal/mol to -6.7 kcal/mol were selected with the control gemcitabine (-5.5 kcal/mol) for further computational analysis after molecular docking. Furthermore, MM/GBSA calculation showed the highest binding energy for the selected docked compounds, which validates their inhibitory potential. Hence, the molecular dynamics simulation, post-simulation analysis, pharmacokinetics model, and DFT results showed that mistletoe compounds are reliable due to their stable interaction with the target protein and drug-likeness properties.

  • Open Access

    Effect of Grafting Rootstock on the Antioxidant Capacity and Content of Heirloom Tomatoes (Solanum lycopersicum L.) in Hydroponic Culture

    by Jamie Greathouse, Shelby Henning, Mette Soendergaard

    Heirloom tomato varieties are in demand by consumers due to high antioxidant levels. However, these varieties are difficult to produce and are prone to disease. To overcome these problems, heirloom tomatoes may be cultivated in hydroponic systems and grafted onto disease-resistant rootstocks. However, it is unknown if the antioxidant content and capacity are affected by grafting. In this study, heirloom (Black Krim and Green Zebra) and standard (Big Beef) varieties were grafted onto wild type (WT) or productive rootstocks (Arnold and Supernatural). The tomatoes were harvested at maturity, freeze-dried, and ground into a powder. Lycopene was extracted using hexane, and the content was determined spectrophotometrically at 503 nm. The antioxidant capacity of methanol extracts was evaluated by the 2,2′-azino-di[3-ethylbenzthiazoline sulfonsyr]sulphonic acid (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays, whereas the phenolic content was determined using the Folin–Ciocalteu assay. Interestingly, the grafting of Big Beef and Green Zebra onto Supernatural rootstock resulted in an increased antioxidant capacity, as determined by the DPPH assay. Moreover, the phenolic content was changed for Big Beef grafted onto Arnold, and Big Beef and Green Zebra grafted onto Supernatural. Taken together, these results indicate that certain combinations of standard and heirloom tomato varieties and productive rootstocks may influence the antioxidant capacity and phenolic content. These results may be used to guide producers when choosing rootstocks for cultivating hydroponic tomatoes.


  • Open Access

    Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides

    by Mallika C. Asar, April Franco, Mette Soendergaard

    Pancreatic cancer is characterized by a 5-year survival rate of 3%, in part due to inadequate detection methods. The small size of peptides offers advantages regarding molecular targeting. Thus, peptides may be used in detection of pancreatic cancer. Here, peptides that target pancreatic cancer cells were selected using phage display technology using a 15-mer fUSE5 library. Phage were pre-cleared against immortalized pancreatic cells (hTERT-HPNE), followed by selections against pancreatic cancer (Mia Paca-2) cells. Next-generation sequencing identified two peptides, MCA1 and MCA2, with a Log2 fold change (Mia Paca-2/ hTERT-HPNE) >1.5. Modified ELISA and fluorescent microscopy showed that both peptides bound significantly higher to Mia Paca-2 cells, and not to hTERT-HPNE, embryonic kidney (HEK 293), ovarian (SKOV-3) and prostate cancer (LNCaP) cell lines. Further characterization of MCA1 and MCA2 revealed EC50 values of 16.11 µM (95% CI [9.69, 26.31 µM]) and 97.01 µM (95% CI [58.64, 166.30 µM]), respectively. Based on these results, MCA1 was selected for further studies. A competitive dose response assay demonstrated specific binding and an IC50 value of 2.15 µM (95% CI [1.28, 3.62 µM]). Taken together, this study suggests that MCA1 may be used as a pancreatic cancer targeting ligand for detection of the disease.


  • Open Access

    Identification of an Indiscriminate Peptide by Phage Display Technology

    by Mallika Asar, Taylor Gunby, April Franco, Che Woodson, Mette Soendergaard

    Phage display has been widely used to develop high‐affinity peptide ligands against proteins and cell lines. Such peptides are typically selected using biopanning to exhibit significant binding affinity and specificity against a molecular target. Rarely are the same peptides identified from separate phage display selections, since the presence of these ligands in a selection typically signify specific binding to the target. However, here, we report the identification of the same peptide (TG1) from two different phage display selections against the hemagglutinin (HA) epitope and human pancreatic cancer (Mia Paca‐2) cells. Phage display selections were conducted to identify a peptide with high affinity and specificity for the HA epitope. In brief, a pre‐cleared 15‐mer fUSE5 phage library was subjected to four rounds of selections against 0.04–4 μg HA. Following the last round of selection, the phage DNA was amplified using PCR and submitted to next‐generation sequencing. These results identified peptide TG1 (RNVPPIFNDVYWIAF) as the most prevalent ligand in the selection. Modified enzyme‐linked immunosorbent assay (ELISA) results showed that 109 nM TG1 bound significantly higher (p10 V/mL pTG1, pancreatic cancer‐targeting pMCA1, or WT phage was incubated with Mia‐Paca‐2, SKOV‐3, or hTERT‐HPNE cells. After washing with Tris‐buffered saline (TBS), bound phage were eluted with 2.5% 3‐cholamidopropyl dimethylammonio 1‐propanesulfonate (CHAPS). Collected phage virions (5 μL) were quantified by qPCR using Fast SYBR Green Master Mix on an Applied Biosystems StepOnePlus Real‐Time qPCR System (Applied Biosystems, CA). The results revealed that pTG1 demonstrated significantly higher binding (p<0.01) compared to WT for all cell lines. As expected, pMCA1 showed binding to Mia‐Paca‐2, and pJ18 exhibited binding to SKOV‐3 cells. Taken together, these results indicate that TG1 indiscriminately binds multiple targets.

  • Open Access

    Antioxidant Capacity and Antiproliferative Activity of Morchella esculenta in Human Ovarian Adenocarcinoma Cells

    by Karissa Scales, Alexander Schlacks, Tyler Parr, Mette Soendergaard

    Morchella esculenta is a coveted wild edible mushroom that has shown antiproliferative activity in various cell lines. However, little is known about the effects of M. esculenta on the cell viability of ovarian cancer. Here, the antiproliferative activity of water, ethanol, and methanol extracts of “grey” and “yellow” M. esculenta fruiting bodies on human ovarian adenocarcinoma cells were investigated. Further, the antioxidant capacity and phenolic content of the mushrooms were evaluated. Wild “grey” and “yellow” M. esculenta fruiting bodies were harvested in Illinois, USA in April 2019, immediately freeze‐dried, and ground into powders. For antioxidant assays, M. esculenta powder was extracted using 1% HCl in 90% aqueous methanol for 2 h. The antioxidant capacity was evaluated using 2,2‐diphenyl‐1‐picrylhydrazyl (DPPH) and 2,2′‐azino‐bis(3‐ethylbenzothiazoline‐6‐sulfonic acid) (ABTS) assays. Both assays revealed significantly (pM. esculenta , respectively. The antioxidant capacity as determined by the ABTS assays was 3.87±0.113 and 9.78±0.112 TE (mean±SEM) for “yellow” and “grey” mushrooms, respectively. The Folin‐Ciocalteu method was used to determine the total phenolic content (gallic acid equivalents; GAE; μmol/g dry weight). In correlation to the DPPH and ABTS results, the phenolic content was significantly higher (p2 . Cell viability was determined using a 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) reduction assay by measuring the absorption of formed formazan at 570 nm. Water and ethanol extracts from both “yellow” and “grey” M. esculenta resulted in significantly reduced cell viability (pM. esculenta significantly lower the cell viability of ovarian adenocarcinoma cells. These mushrooms may, therefore, exhibit antiproliferative potential against ovarian cancer cells.


  • Open Access

    Ovarian Cancer Targeting Phage for In Vivo Near-Infrared Optical Imaging

    by Mallika Asar, Jessica Newton-Northup, Susan Deutscher, Mette Soendergaard

    Ovarian cancer is often diagnosed at late stages due to current inadequate detection. Therefore, the development of new detection methods of ovarian cancer is needed. This may be achieved by phage nanoparticles that display targeting peptides for optical imaging. Here, two such phage clones are reported. Ovarian cancer binding and specificity of phage clones (pJ18, pJ24) and peptides (J18, J24) were investigated using fluorescent microscopy and modified ELISA. Further, AF680-labeled phage particles were subjected to biodistribution and optical imaging studies in SKOV-3 xenografted mice. Fluorescent microscopy and ELISA of phage and peptides showed significantly increased binding to SKOV-3 cells compared to controls. Additionally, these studies revealed that J18 exhibits specificity for ovarian cancer SKOV-3 and OVCAR-3 cell lines. Further, peptides displayed increased SKOV-3 binding compared to N35 (non-relevant peptide) with EC50 values of 22.2 ± 10.6 μM and 29.0 ± 6.9 (mean ± SE), respectively. Biodistribution studies of AF680-labeled phage particles showed tumor uptake after 4 h and excretion through the reticuloendothelial system. Importantly, SKOV-3 tumors were easily localized by optical imaging after 2 h and 4 h and displayed good tumor-to-background contrast. The fluorescent tumor signal intensity was significantly higher for pJ18 compared to wild type (WT) after 2 h.


  • Open Access

    Determination of Fd‐tet Bacteriophage Infectivity of E. coli B91BK Under Conditions that Disrupt the Biotin‐Streptavidin Interaction

    by Taylor Marie Gunby, Mette Soendergaard

    Bacteriophage (phage) are commonly used in techniques such as phage display due to their ability to express large foreign proteins on various coat proteins, and to be easily propagated in E. coli . Validation of selected phage particles in binding assays often involves biotinylation of the virion to facilitate probing by streptavidin. Phage may be collected following validation assays and propagated for further analysis by breaking the biotin‐streptavidin interaction. However, little is known about the effects on E. coli infectivity of the harsh conditions (95% formamide, >90°C) typically utilized to disrupt the biotin‐streptavidin complex. The E. coli (K91BK) infectivity of wild type (WT) Fd‐tet phage was determined in Tris buffered saline (TBS; pH 7.5), and 10 mM ethylenediaminetetraacetic acid (EDTA), 95% formamide (EDTA‐formamide) at temperatures up to 100°C. In brief, 10 12 phage particles (virions) were incubated in TBS or EDTA‐formamide for 10 min at 25–100°C (5°C increments). The infectivity of E. coli was then determined by quantifying the number of transducing units (TU). To do so, various dilutions of phage were incubated with E. coli K91BK (OD 600 =0.2 of 1/10 dilution) in terrific broth (TB) and allowed to infect for 10 min at room temperature. Next, NZ amine, yeast extract (NZY) medium was added and then incubated at 37°C for 30 min to promote propagation. Finally, the culture was plated on NZY agar plates with 100 μg/mL kanamycin and 20 μg/mL tetracycline and grown overnight at 37°C. The resulting colonies were counted, and used to calculate TU/mL. Results showed that the TU/mL was lowered significantly (p0.05). This is mostly likely due to reduced TU/mL already observed at 25°C in EDTA‐formamide compared to TBS, thereby lowering the relative decrease. While a trend of lower TU/mL for EDTA‐formamide compared to TBS was observed, this difference was not significantly lower at high temperatures (>75°C; p>0.05), indicating that the former does not comparatively decrease E. coli infectivity. At temperatures known to disrupt the biotin‐streptavidin interaction (>90°C), both treatments reduced the infectivity compared to 25°C from approximately 10 10 to 10 9 TU/mL, corresponding to a factor of 10. While these results show that increasing temperature overall decreases the number of phage capable of transduction, a sufficiently high number of virions maintain the ability to infect E. coli . Thus, biotinylated phage may be released from streptavidin by disrupting the interaction using temperatures above 90°C and utilization of EDTA‐formamide. Such phage may subsequently be amplified by propagation in E. coli and utilized in further experiments. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .